ATRA Atara Biotherapeutics

Atara Biotherapeutics, Inc.(@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With its lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Its platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel® in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients' lives is its mission and it will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and its leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.

Company profile

Pascal Touchon
Fiscal year end
Atara Biotherapeutics Australia • Atara Biotherapeutics Ireland Limited • Atara Biotherapeutics Netherlands B.V. • Atara Biotherapeutics Switzerland GmbH ...

ATRA stock data



9 Aug 21
26 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 125.25M 125.25M 125.25M 125.25M 125.25M 125.25M
Cash burn (monthly) 9.08M (positive/no burn) 28M 26.56M 20.53M 15.36M
Cash used (since last report) 35.24M n/a 108.66M 103.07M 79.65M 59.61M
Cash remaining 90.01M n/a 16.59M 22.18M 45.6M 65.64M
Runway (months of cash) 9.9 n/a 0.6 0.8 2.2 4.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
22 Sep 21 Joe Newell Common Stock Sell Dispose S No Yes 17 10,500 178.5K 119,929
22 Sep 21 Joe Newell Common Stock Option exercise Acquire M No Yes 12.15 10,500 127.58K 130,429
22 Sep 21 Joe Newell Employee Stock Option Common Stock Option exercise Dispose M No Yes 17 2,125 36.13K 10,625
22 Sep 21 Joe Newell Employee Stock Option Common Stock Option exercise Dispose M No Yes 17 8,375 142.38K 34,875
15 Sep 21 Joe Newell Common Stock Sell Dispose S No Yes 15.6121 3,116 48.65K 119,929
30 Aug 21 Joe Newell Common Stock Sell Dispose S No Yes 15 3,500 52.5K 123,045
17 Aug 21 Dupont Jakob Common Stock Sell Dispose S No Yes 12.532 2,152 26.97K 92,793
17 Aug 21 Amar Murugan Common Stock Sell Dispose S No Yes 12.532 2,080 26.07K 89,664

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 141 148 -4.7%
Opened positions 18 23 -21.7%
Closed positions 25 21 +19.0%
Increased positions 46 61 -24.6%
Reduced positions 52 42 +23.8%
13F shares
Current Prev Q Change
Total value 1.32B 1.87B -29.0%
Total shares 85.19M 85.79M -0.7%
Total puts 27.3K 19.6K +39.3%
Total calls 23.1K 65.4K -64.7%
Total put/call ratio 1.2 0.3 +294.3%
Largest owners
Shares Value Change
Baupost 8.48M $131.83M 0.0%
BLK Blackrock 7.72M $120.05M +11.1%
Maverick Capital 7.7M $119.81M +14.3%
JPM JPMorgan Chase & Co. 7.51M $116.85M +12.0%
Vanguard 6.7M $104.25M +5.5%
Redmile 6.45M $100.29M -6.3%
STT State Street 4.37M $67.98M -0.9%
MS Morgan Stanley 3.04M $47.21M -4.6%
GS Goldman Sachs 2.6M $40.4M +22.4%
Wasatch Advisors 2.39M $37.14M +17.5%
Largest transactions
Shares Bought/sold Change
Consonance Capital Management 0 -1.67M EXIT
Assenagon Asset Management 1.5M +1.5M NEW
DB Deutsche Bank AG - Registered Shares 275.78K -1.32M -82.7%
CS Credit Suisse 1.23M -1.28M -50.9%
Maverick Capital 7.7M +965.27K +14.3%
JPM JPMorgan Chase & Co. 7.51M +806.19K +12.0%
BLK Blackrock 7.72M +770.92K +11.1%
Artal 1.5M -500K -25.0%
GS Goldman Sachs 2.6M +475.98K +22.4%
Two Sigma Investments 483.45K -472.26K -49.4%

Financial report summary

  • We have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the foreseeable future.
  • We have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability.
  • We currently have no approved products and thus have no product revenues. We may never generate revenues from the sale of products or achieve profitability.
  • We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.
  • Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on terms that are unfavorable to us.
  • We are generally early in our development efforts and have only a small number of product candidates in clinical development. All of our other product candidates are still in preclinical development. If we or our collaborators are unable to successfully develop and commercialize product candidates or experience significant delays in doing so, our business may be materially harmed.
  • Our business and operations have been affected by and could be materially and adversely affected in the future by the effects of health epidemics and pandemics, including the evolving and ongoing effects of the COVID-19 pandemic. The COVID-19 pandemic continues to impact our business and operations and could materially and adversely affect our business and operations in the future, as well as the businesses and operations of third parties on which we rely.
  • Our future success is dependent on the regulatory approval of our product candidates.
  • Our T-cell immunotherapy product candidates and our next-generation CAR T programs represent new therapeutic approaches that could result in heightened regulatory scrutiny, delays in clinical development or delays in or our inability to achieve regulatory approval, commercialization or payor coverage of our product candidates.
  • The results of preclinical studies or earlier clinical studies are not necessarily predictive of future results. Our existing product candidates in clinical studies, and any other product candidate we advance into clinical studies, may not have favorable results in later clinical studies or receive regulatory approval.
  • Interim “top line” and preliminary data from clinical studies that we or our partners may announce or share with regulatory authorities from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.
  • We may not be able to obtain or maintain orphan drug exclusivity for our product candidates.
  • BTD by the FDA and PRIME designation by the EMA may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.
  • Failure to obtain regulatory approval in international jurisdictions would prevent our product candidates from being marketed abroad.
  • Even if our product candidates receive regulatory approval, they may still face future development and regulatory difficulties.
  • Regulations, guidelines and recommendations published by various government agencies and organizations may affect the use of our product candidates.
  • We may not successfully identify, acquire, develop or commercialize new potential product candidates.
  • We may not realize the benefits of strategic alliances that we may form in the future or of potential future product acquisitions or licenses.
  • We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates.
  • We intend to manufacture a majority of our product candidates ourselves. Delays in receiving regulatory approvals for product candidates produced in our manufacturing facility could delay our development plans and thereby limit our ability to generate revenues.
  • If our sole clinical or commercial manufacturing facility or our CMO is damaged or destroyed or production at these facilities is otherwise interrupted, our business would be negatively affected.
  • Maintaining clinical and commercial timelines is dependent on our end-to-end supply chain network to support manufacturing; if we experience problems with our third party suppliers we may delay development and/or commercialization of our product candidates.
  • If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our ability to commercialize our product candidates successfully and to compete effectively may be adversely affected.
  • If we are sued for infringing the intellectual property rights of third parties, the resulting litigation could be costly and time-consuming and could prevent or delay our development and commercialization efforts.
  • We may not be able to protect our intellectual property rights throughout the world.
  • We have in-licensed a significant portion of our intellectual property from our partners. If we breach any of our license agreements with these partners, we could lose the ability to continue the development and potential commercialization of one or more of our product candidates.
  • We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful and have a material adverse effect on the success of our business.
  • If we are unable to protect the confidentiality of our trade secrets and other proprietary information, the value of our technology could be materially adversely affected and our business could be harmed.
  • Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, healthcare payors and the medical community, including hospitals and outpatient clinics.
  • Even if we are able to commercialize our product candidates, the products may not receive coverage and adequate reimbursement from third-party payors in the U.S. and in other countries in which we seek to commercialize our products, which could harm our business.
  • Current and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain regulatory approval of and commercialize our product candidates and affect the prices we may obtain.
  • Price controls may be imposed in foreign markets, which may adversely affect our future profitability.
  • We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
  • We may need to grow the size of our organization, and we may experience difficulties in managing this growth.
  • Our stock price has been and will likely continue to be volatile and may decline regardless of our operating performance.
  • Our principal stockholders own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.
  • We have incurred and will continue to incur increased costs as a result of being a public company and our management expects to devote substantial time to public company compliance programs.
  • Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be the sole source of potential gain for our stockholders.
  • Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
  • If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.
  • Our future success depends on our ability to retain our executive officers and to attract, retain and motivate qualified personnel.
  • Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse, privacy and other laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
  • Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.
  • Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.
  • If we and our third-party manufacturers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
  • The actual or perceived failure by us, our customers, or vendors to comply with increasingly stringent laws, regulations and contractual obligations relating to privacy, data protection, and data security could harm our reputation, and subject us to significant fines and liability.
  • If our security measures are compromised, or our information technology systems or those of our vendors, and other relevant third parties fail or suffer security breaches, loss or leakage of data, and other disruptions, this could result in a material disruption of our services, compromise sensitive information related to our business, harm our reputation, trigger our breach notification obligations, prevent us from accessing critical information, and expose us to liability or other adverse effects to our business.
  • Our ability to use net operating loss carryforwards and certain tax assets to offset future taxable income or taxes may be subject to certain limitations.
  • Business disruptions could seriously harm our future revenues and financial condition and increase our costs and expenses.
Management Discussion
  • License and collaboration revenue for the three months and six months ended June 30, 2021 consisted of revenue related to the recognition of upfront license fees, fees for research, process development and translational activities, and technology transfer and manufacturing service fees under the Bayer Agreements. No revenue was recognized in 2020.
  • Tab-cel® expenses were $12.8 million and $24.7 million in the three and six months ended June 30, 2021, respectively, as compared to $14.9 million and $29.7 million in the comparative 2020 periods. The decreases in 2021 were primarily due to higher production activities in 2020 related to the build-up of our tab-cel® inventory.
  • ATA188, CAR T and other program expenses were $7.6 million and $16.7 million in the three and six months ended June 30, 2021, respectively, as compared to $6.1 million and $10.2 million in the comparative 2020 periods. The increases were primarily related to milestone and license fees due to MSK and QIMR, and an increase in research and clinical trial costs to further advance ATA188 and our CAR T programs.
Content analysis
H.S. junior Avg
New words: abeyance, Accellion, adapted, arguing, attack, behavior, biomarker, central, CJEU, clarity, CMSC, Consortium, correctly, dismissed, display, EMBOLD, exit, expedited, extraterritorial, imaging, ingredient, lawsuit, lodge, magnetization, MTR, myelination, notified, Rapporteur, ratio, real, referendum, regular, relieve, satisfaction, stipulated, supervisory, supplementary, timeline, tolebrutinib, UK, undue, unvaried, version, vi, viii, virtue, waive
Removed: beneficiary, Blueprint, calling, Canada, cap, Circuit, circumvent, death, entirety, hematopoietic, informally, Judge, KEYTRUDA, laid, Merck, negotiating, pembrolizumab, pocket, programmed, proposal, RCT, remaining, remanded, repealed, resistant, reverse, ruled, situation, transplantation, upheld